Other FDA Approved

Rezafungin

A once-weekly semisynthetic echinocandin lipopeptide antifungal that inhibits fungal 1,3-beta-D-glucan synthase, FDA approved on March 22, 2023 as Rezzayo for candidemia and invasive candidiasis in patients with limited or no alternative options, with a transplant-prophylaxis trial completed in 2026.

AntifungalEchinocandinLipopeptideGlucan SynthaseFDA Approved

Also referenced as: CD101, Rezafungin acetate, Rezzayo

Also appears in: Immune

Public product evidence No certificate records are bound to a tracked Rezafungin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Rezafungin product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This compound maps to at least one regulated medical product or label context in the United States.

Research area
Other research areas

Primary research area: Other. Also surfaces under Immune for browsing and discovery.

Body systems
Immune · Systemic

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
3

CD101, Rezafungin acetate, Rezzayo

Signal depth
High

FDA label signal · 11 trials · 400 PubMed results

Established

Rezafungin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Rezafungin has 10 name-matched clinical trials (highest phase: Phase 4) and 400 PubMed-indexed publications and holds an FDA drug label. 2 trials have posted results.

FAERS (approved drug): 86
Human data
Approved drug
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Rezafungin?

Rezafungin is a semisynthetic lipopeptide antifungal of the echinocandin class, the same family as caspofungin, micafungin and anidulafungin: a cyclic hexapeptide core carrying a lipophilic side chain, synthesized from a fermentation product of the fungus Aspergillus nidulans. It is a peptide by structure but not a hormone or signaling peptide; it acts on an enzyme found only in fungal cell walls. The marketed form is rezafungin acetate, with the empirical formula C63H85N8O17·C2H3O2 and a formula weight of 1,285.46 g/mol according to the US label. It was developed as CD101 by Seachaid Pharmaceuticals and then Cidara Therapeutics; Mundipharma holds the new drug application and Melinta Therapeutics is the US labeler.

What distinguishes rezafungin from the earlier echinocandins is pharmacokinetic rather than microbiological: it is stable enough to be given as a once-weekly intravenous infusion, where caspofungin, micafungin and anidulafungin require daily infusions. It is approved in the United States as Rezzayo for candidemia and invasive candidiasis in patients with limited or no alternative options, and in the European Union and United Kingdom for invasive candidiasis in adults. Rezafungin is a hospital antifungal with essentially no footprint in the research-peptide market.

How it works

  • Inhibition of 1,3-beta-D-glucan synthase. The US label describes rezafungin as an inhibitor of the 1,3-beta-D-glucan synthase enzyme complex, present in fungal cell walls but not in mammalian cells; blocking it prevents formation of an essential wall polymer and gives concentration-dependent fungicidal activity against Candida in vitro. Cryo-EM structures of the yeast catalytic subunit Fks1 and of an echinocandin-resistant mutant place the active site at the membrane-cytoplasm interface with a glucan translocation path spanning the bilayer, and show resistance mutations clustering near transmembrane helices 5, 6 and 8 (Hu et al., Nature, 2023;616(7955):190-198). Reduced susceptibility arises mainly from “hot spot” mutations in FKS1 and FKS2, to which the label says rezafungin shows some degree of cross-resistance.
  • Stability engineered against anidulafungin’s weak point. Rezafungin is a structural analog of anidulafungin designed to remove that drug’s chemical lability. After 44 hours at 37 °C in rat, dog, monkey and human plasma, 91%, 79%, 94% and 93% of rezafungin remained versus 7%, 15%, 14% and 7% of anidulafungin, and the lyophilized powder lost less than 2% after nine months at 40 °C (Krishnan et al., Journal of Antibiotics, 2017;70(2):130-135). Anidulafungin generated a reactive species in a glutathione trapping experiment and caused hepatic and hematologic toxicity in a repeat-dose rat study at comparable exposures; rezafungin did neither (Ong et al., Antimicrobial Agents and Chemotherapy, 2016;60(11):6872-6879).
  • A half-life measured in days. In two placebo-controlled dose-escalation studies in healthy adults, single and weekly doses up to 400 mg gave dose-proportional exposure, accumulation of only 30 to 55%, a half-life above 80 hours and minimal urinary excretion (Sandison et al., Antimicrobial Agents and Chemotherapy, 2017;61(2):e01627-16). The label’s population estimate in patients is a terminal half-life of 152 ± 29 hours; hepatic metabolism has not been observed, 74.3% of recovered radioactivity appears in feces mainly as unchanged drug, and renal or hepatic impairment has no clinically relevant effect on exposure.
  • Spectrum matches the class. Against 2,205 invasive isolates collected worldwide from 2016 to 2018, rezafungin inhibited 99.8% of Candida albicans, 95.7% of Candida glabrata, 97.4% of Candida tropicalis and 100% of Candida krusei isolates, with higher MICs for Candida parapsilosis (MIC50/90 of 1/2 µg/mL) as seen with other echinocandins, class-typical activity against Aspergillus fumigatus and Aspergillus flavus, and limited activity against Cryptococcus neoformans (Pfaller et al., Antimicrobial Agents and Chemotherapy, 2020;64(4):e00099-20). In neutropenic mice infected with Candida auris, the AUC/MIC ratio predicted efficacy (R2 = 0.76) (Lepak et al., Antimicrobial Agents and Chemotherapy, 2018;62(11):e01572-18).

Research status

Preclinical prophylaxis models. In immunosuppressed mice, rezafungin reduced Candida burden, improved survival in aspergillosis and prevented Pneumocystis murina pneumonia with activity comparable to trimethoprim-sulfamethoxazole at human-equivalent doses (Miesel et al., Antimicrobial Agents and Chemotherapy, 2021;65(3):e01992-20; Cushion and Ashbaugh, Journal of Fungi, 2021;7(9):747).

STRIVE phase 2 (NCT02734862). A double-blind trial at 44 centers in 10 countries randomized 207 adults with candidemia or invasive candidiasis to rezafungin 400 mg weekly, rezafungin 400 mg then 200 mg weekly, or daily caspofungin for up to four weeks. In the 183-patient microbiological intention-to-treat population, overall cure at day 14 was 60.5%, 76.1% and 67.2% respectively and 30-day all-cause mortality was 15.8%, 4.4% and 13.1% (Thompson et al., Clinical Infectious Diseases, 2021;73(11):e3647-e3655). The 400 mg/200 mg regimen was carried forward.

ReSTORE phase 3 (NCT03667690). The pivotal double-blind, double-dummy trial at 66 centers in 15 countries randomized 199 adults with confirmed candidemia or invasive candidiasis 1:1 to once-weekly rezafungin (400 mg then 200 mg, two to four doses) or daily caspofungin between October 12, 2018 and August 29, 2021. Two primary endpoints were tested against a 20% noninferiority margin in the 187-patient modified intention-to-treat population: day 14 global cure, the European endpoint, was 59% (55 of 93) with rezafungin and 61% (57 of 94) with caspofungin, a weighted difference of −1.1% (95% CI −14.9 to 12.7); 30-day all-cause mortality, the FDA endpoint, was 24% (22 of 93) versus 21% (20 of 94), a difference of 2.4% (95% CI −9.7 to 14.4). Treatment-emergent adverse events occurred in 91% versus 85% and serious adverse events in 56% versus 53% (Thompson et al., Lancet, 2023;401(10370):49-59). A pooled analysis of STRIVE and ReSTORE (139 versus 155 patients) found 30-day mortality of 19% in each arm and mycological eradication by day 5 in 73% versus 65%, attributed to front-loaded weekly exposure (Thompson et al., Lancet Infectious Diseases, 2024;24(3):319-328). A Chinese cohort recruited for regulatory purposes brought the combined ReSTORE population to 246, and noninferiority held on both endpoints (30-day mortality 25.2% versus 24.8%; day 14 global cure 56.5% versus 57.3%) (Thompson et al., Open Forum Infectious Diseases, 2025;12(9):ofaf555).

ReSPECT phase 3 prophylaxis (NCT04368559). The double-blind trial, started May 11, 2020 and completed January 29, 2026, randomized 602 adults undergoing allogeneic blood and marrow transplantation at more than 50 centers in seven countries to once-weekly rezafungin or a standard regimen of an azole (posaconazole or fluconazole) plus trimethoprim-sulfamethoxazole. According to sponsor releases, which are not peer reviewed and whose results had not been posted on ClinicalTrials.gov, fungal-free survival at day 90 was 60.7% with rezafungin and 59.0% with the standard regimen, meeting noninferiority. The sponsor states that the data were submitted to the FDA and EMA and that the FDA granted priority review; no decision had been announced as of November 2026.

Other formulations and pediatrics. A phase 1 subcutaneous study in healthy adults was terminated after the 10 mg cohort over concern about injection-site reaction severity, although no predefined halting criterion was met, and the authors suggested reformulation before any further subcutaneous work (Gu et al., Clinical and Translational Science, 2022;15(7):1592-1598). A phase 1 pharmacokinetic study in children under 18 years (NCT05534529), begun September 13, 2023, was terminated for recruitment difficulties. The FDA nevertheless approved supplement S-007 on July 16, 2026, from an application received September 25, 2025, extending the indication to patients 12 to under 18 years on the basis of adult data and population pharmacokinetic modeling; the label states that no clinical studies were conducted in pediatric patients and that safety and effectiveness below 12 years have not been established.

Regulatory path. The FDA approved Rezzayo under NDA 217417 on March 22, 2023 for candidemia and invasive candidiasis in adults with limited or no alternative options, stating in the label that approval rests on limited clinical safety and efficacy data and that safety has not been established beyond four weekly doses. Drugs@FDA lists a labeling supplement approved December 10, 2025, which added a warning on serious hypersensitivity reactions including anaphylaxis, and the July 16, 2026 adolescent supplement. The European Commission granted an EU-wide marketing authorization on December 22, 2023 for invasive candidiasis in adults, with Mundipharma GmbH as holder; the EMA’s summary notes uncertainty from the relatively small pivotal study but concluded that the benefits outweigh the risks. The UK Medicines and Healthcare products Regulatory Agency approved Rezzayo on January 29, 2024. No approval in Japan, China or Canada was identified as of November 2026.

Common dosage forms

  • Rezzayo for injection. Single-dose 20 mL glass vials of lyophilized rezafungin acetate equivalent to 200 mg of rezafungin, a white to pale yellow cake or powder, given as an intravenous infusion by hospital clinicians; the only marketed presentation in the US, EU and UK.
  • Investigational subcutaneous formulation. Studied in one phase 1 study and never marketed.
  • No other presentation. No oral, topical or inhaled rezafungin product exists.

Key considerations

  • Regulatory status. The FDA Approved status reflects the March 22, 2023 approval of Rezzayo (rezafungin for injection) under NDA 217417 for candidemia and invasive candidiasis in patients with limited or no alternative options. The indication was extended to patients 12 years and older on July 16, 2026, the EU authorized the product on December 22, 2023 and the UK on January 29, 2024, and the transplant-prophylaxis indication from ReSPECT remains under review rather than approved.
  • A narrow, caveated label. The US indication is restricted to patients with limited or no alternatives, the label says approval is based on limited data, and safety beyond four weekly doses has not been studied, because the pivotal evidence is a 199-patient noninferiority trial with a 20% margin. The EMA accepted the same uncertainty for an unrestricted adult indication.
  • Weekly dosing is the point, not potency. Rezafungin’s in vitro activity, species coverage and FKS-mediated resistance pattern track those of caspofungin, micafungin and anidulafungin; its distinguishing properties are chemical stability, a terminal half-life of about 152 hours, no hepatic metabolism and no clinically relevant interactions with cytochrome P450 substrates or transporters, including cyclosporine and tacrolimus. Faster early culture clearance in the pooled analyses is attributed to front-loaded exposure and has not been tested as a primary endpoint.
  • Safety signals to weigh. Adverse events in the pivotal trials matched caspofungin, with hypokalemia, pyrexia, diarrhea, anemia and vomiting the most frequent reactions on rezafungin, and post-marketing anaphylaxis reports prompted the December 2025 label change.
  • A lipopeptide, and not an alias of its siblings. Rezafungin, rezafungin acetate, CD101 and Rezzayo denote one molecule; caspofungin, micafungin and anidulafungin are separate echinocandins with their own approvals, and the preclinical toxicity comparison with anidulafungin is not a clinical superiority claim.